Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Maine.
Press releases published on June 30, 2025
EVA制药与浙江金华康恩贝生物制药签署战略供应协议
GlobeNewswire
·
June 30, 2025
上海，开罗, June 30, 2025 (GLOBE NEWSWIRE) -- EVA制药公司，作为推动中东和非洲地区医疗创新与可及性的领先制药企业之一，与浙江金华康恩贝生物制药集团，中国最著名的制药集团之一，签署了战略供应协议，标志着全球医疗合作迈出了重要一步。 该协议在2025年中国国际医药原料药展（CPHI China 2025）期间签署，代表了各自地区内两个有影响力企业之间的高层合作。该协议旨在支持更可持续、更灵活和更安全的药品供应链，最终为新兴市场的患者提供更大的可及性。 …
Clover Health Set to Join Russell 3000® Index
GlobeNewswire
·
June 30, 2025
WILMINGTON, Del., June 30, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), announced that it is set to join the broad-market Russell 3000® Index, effective after the US market opens today, June 30, 2025, as part …
Minovia Therapeutics Announces FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in Pearson Syndrome
GlobeNewswire
·
June 30, 2025
Haifa, ISRAEL, June 30, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U. …
Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study
GlobeNewswire
·
June 30, 2025
Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer pain, supporting …
Microbot Medical® Added to the Russell Microcap® Index
GlobeNewswire
·
June 30, 2025
HINGHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it was added as a member of the Russell Microcap® Index. Microbot Medical’s addition …
Ashvattha Therapeutics Presents Positive Interim Phase 2 Results for Subcutaneous Migaldendranib Treatment for DME and Wet-AMD at 2025 MaculArt Meeting
GlobeNewswire
·
June 30, 2025
Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with DME and wet-AMD Novel subcutaneous delivery may offer a more patient-friendly alternative to intravitreal injections, with the potential to …
23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation
GlobeNewswire
·
June 30, 2025
SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a genetics-led consumer healthcare company, today announced that it has received approval from the U.S. Bankruptcy Court for the Eastern …
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
GlobeNewswire
·
June 30, 2025
TARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway …
Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions
GlobeNewswire
·
June 30, 2025
RIYADH, Saudi Arabia and ISTANBUL and OXFORDSHIRE, United Kingdom, June 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced that they have been appointed by …
Synergy CHC Corp. (NASDAQ: SNYR) Secures Landmark Retail and Distribution Wins Across North America for FOCUSfactor Supplements and Functional Beverages
GlobeNewswire
·
June 30, 2025
WESTBROOK, Maine, June 30, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a fast-growing consumer health and wellness company, today announced a major wave of North American retail and distribution gains across both …
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
GlobeNewswire
·
June 30, 2025
– Study will evaluate safety and antiviral activity of ABI-1179 in participants with recurrent genital herpes – – ABI-1179 IND cleared to support study expansion to sites in United States – – Phase 1b studies for ABI-1179 and ABI-5366 running concurrently …
IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq’s Listing Requirement, Anticipates Additional Compliance Period
GlobeNewswire
·
June 30, 2025
LAWRENCEVILLE, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that, in consultation with The Nasdaq Stock Market LLC (Nasdaq), it has …
SPR Receives Fourth Consecutive Northeast Ohio Top Workplaces Award
GlobeNewswire
·
June 30, 2025
- Based on employee feedback highlighting strong corporate culture - CLEVELAND, June 30, 2025 (GLOBE NEWSWIRE) -- For the fourth year in a row, SPR has been recognized as a Top Workplace by Northeast Ohio Top Workplaces. This recognition is based solely on …
Tilde Sciences Announces Availability Of VECAMYL™ (Mecamylamine) With Exclusive Distribution Through Optime Care Specialty Pharmacy
GlobeNewswire
·
June 30, 2025
JERSEY CITY, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tilde Sciences LLC (“Tilde”), a U.S.–based biopharmaceutical company dedicated to developing therapies for rare diseases with significant unmet need, today announced the nationwide availability of …
HealthLynked Appoints Andrew Mavliev as Chief Technology and Product Officer to Accelerate Direct-to-Consumer Healthcare Innovation
GlobeNewswire
·
June 30, 2025
NAPLES, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK), a leader in connected healthcare technology, is pleased to announce the appointment of Andrew Mavliev as its new Chief Technology and Product Officer. With over 15 …
Tectonic Therapeutic Joins Russell 3000® Index
GlobeNewswire
·
June 30, 2025
WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of …
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors
GlobeNewswire
·
June 30, 2025
REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc. (Nasdaq: …
Spectral AI Announces Submission to FDA of its DeepView® System
GlobeNewswire
·
June 30, 2025
DALLAS, June 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 …
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
GlobeNewswire
·
June 30, 2025
SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its addition to the Russell 2000® …
Protara Therapeutics Announces Addition to the Russell 3000® Index
GlobeNewswire
·
June 30, 2025
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has been added as a member …